Target Substance Phase NCT number (https://clinicaltrials.gov/ ) Indication SS/CTCL Indication AD Approved for (in Europe) Comments (more information & references in text) CCR4 Mogamulizumab (KW-0761) 3 NCT01728805 X Current study in comparison to HDAC inhibitor CD3 A-dmDT390-bisFv(UCHT1) Immunotoxin 2 NCT00611208 X Not likely to be used in AD CD25 Denileukin diftitox na X CTCL Not likely to be used in AD CD52 Alemtuzumab na X Multiple sclerosis Had been withdrawn from the market for CTCL and newly approved for multiple sclerosis (no medical reasons), not likely to be used in AD CTLA4 Ipilimumab na Malignant melanoma Interesting in CTCL, less in AD, combination study with nivolumab, ipilimumab, and brentuximab in HL ongoing CXCR4 Plerixafor na Used in AML, interesting for SS/CTCL IL-4R Dupilumab (REGN668) 3 NCT02277769 X Interesting as well in CTCL Pitrakinra 2 NCT00676884 X IL-12 NM-IL-12 2 NCT02542124 X In combination with TSEB IL-13 Lebrikizumab (TNX-650) 2 NCT02340234 X Has been studied in NHL in phase 1, data not yet available Tralokinumab 2 NCT02347176 X IL-18 SB-485232 na In phase 2 in NHL, interesting in CTCL, controversial opinions for use in AD IL-22 Fezakinumab (ILV-094) 2 NCT01941537 Potentially interesting in SS/CTCL PD-1 Pembrolizumab (MK-3475) 2 NCT02243579 X Both in malignant melanoma Not likely to be used in AD, combination study with nivolumab, ipilimumab & brentuximab in HL ongoing Nivolumab na PD-L1 Avelumab na In phase 1 in HL, interesting in SS/CTCL TLR7 Imiquimod na X Basal cell carcinoma, actinic keratoses, and genital warts Topical application, leading to inflammatory reactions, not promising for AD TLR9 CPG 7909 1 NCT00043420 X Interesting because of subcutaneous application (no restriction to skin surface)
